The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab alone or in combination with relatlimab or ipilimumab in resectable head and neck squamous cell carcinoma (HNSCC).
 
Robert L. Ferris
Stock and Other Ownership Interests - Novasenta
Consulting or Advisory Role - Achilles Therapeutics; Adagene; Aduro Biotech; Bicara Therapeutics; Bristol-Myers Squibb; Cantenion; Coherus Biosciences; Eterna Therapeutics; Everest Clinical Research; F. Hoffmann LaRoche; Genocea Biosciences; Hookipa Pharma; Instil Bio; Kowa Research Institute; Lifescience Dynamics; Macrogenics; MeiraGTx; Merck; Mirati Therapeutics; Mirror Biologics; Nanobiotix; Novartis; Novasenta; Numab; OncoCyte; Pfizer; PPD; Rakuten Medical; Sanofi; Seagen; SIRPant Immunotherapeutics; VIR Biotechnology; Zymeworks; Zymeworks
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Novasenta; Tesaro
 
William E. Gooding
No Relationships to Disclose
 
Simion I. Chiosea
No Relationships to Disclose
 
Umamaheswar Duvvuri
Consulting or Advisory Role - ACTIVARTIS Biotech; Intuitive Surgical
Research Funding - Biomarin (Inst); Kolltan Pharmaceuticals (Inst); Medrobotics (Inst)
 
Seungwon Kim
No Relationships to Disclose
 
Mark Kubik
No Relationships to Disclose
 
Shaum Sridharan
No Relationships to Disclose
 
Moon Jung Fenton
No Relationships to Disclose
 
Heath Devin Skinner
No Relationships to Disclose
 
Zahra Rahman Kelly
No Relationships to Disclose
 
Housaiyin Li
No Relationships to Disclose
 
Lazar Vujanovic
Patents, Royalties, Other Intellectual Property - Co-inventor of a methodology licensed to INmune Bio, Inc. where DN-TNF can be used to prevent or treat malignancies.
 
Dan Paul Zandberg
Consulting or Advisory Role - Blueprint Medicines; Macrogenics; Merck; Prelude Therapeutics
Research Funding - Aduro Biotech (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); EMD Serono (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)